What is the mechanism of action of anti-tumour necrosis factor-α antibody in rheumatoid arthritis?

International Archives of Allergy and Immunology

Volumn 111, Issue 4, 1996, Pages 362-365

  Feldmann, Marc ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Autoimmunity; Immunotherapy; Rheumatoid arthritis; Tumour necrosis factor

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ANTIBODY;

DISEASE ACTIVITY; DRUG MECHANISM; HUMAN; JOINT; LEUKOCYTE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS;

ANIMALS; ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; AUTOIMMUNITY; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOTHERAPY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0029837629     PISSN: 10182438     EISSN: 14230097     Source Type: Journal    
DOI: 10.1159/000237393     Document Type: Article

References (24)

1. Erhard CC, Mumford PA, Venables PJW, Mai-ni RN: Factors predicting a poor life prognosis in rheumatoid arthritis: An eight year prospective study, Ann Rheum Dis 1989;48:7-13.
2. Feldmann M, Brennan FM, Maini RN: Role of cytokines in rheumatoid arthritis, Annu Rev Immunol 1996;14:397-440.
3. Di Giovinc FS, Nuki G, Duff GW: Tumour necrosis factor in synovial exudates, Ann Rheum Dis 1988;47:768-772.
4. Alvaro-Garcia JM, Zvaifler NJ, Firestein GS: Cytokines in chronic inflammatory arthritis, IV GM-CSF mediated induction of class II MHC antigen on human monocytes: A possible role in RA, J Exp Med 1989;146:865-875.
5. Buchan G, Barrett K, Fujita T, Taniguchi T, Maini RN, Feldmann M: Detection of activated T cell products in the rheumatoid joint using cDNA probes to interleukin-2 (IL-2) receptor and IFN-y, Clin Exp Immunol 1988:71:295-301.
6. Buchan G, Barrett K, Turner M, Chantry D, Maini RN, Feldmann M: Interleukin-1 and tumour necrosis factor mRNA expression in rheumatoid arthritis: Prolonged production of IL-la, Clin Exp Immunol 1988;73:449-455.
7. Saklatavala I, Sarsfield SJ, Townsend Y: Purification of two immunologicaily different leucocyte proteins that cause cartilage resorption lymphocyte activation and fever, J Exp Med 1985;162:1208-1215.
8. Brennan FM, Chantry D, Jackson A, Maini RN, Feldmann M: Inhibitory effect of TNFu antibodies on synovial cell interleukin-1 production in rheumatoid arthritis, Lancet 1989;ii:244-247.
9. Haworth C, Brennan FM, Chantry D, Turner M, Maini RN, Feldmann M: Expression of granu-locytc-macrophagc colony-stimulating factor in rheumatoid arthritis: Regulation by tumor necrosis factor-a, Eur J Immunol 1991;21: 2575-2579.
10. Butler DM, Feldmann M, Brennan FM: Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures, Comparison of monoclonal anti-TNFa antibody with the IL-I receptor antagonist, Eur Cytokine Nctw 1995;6:225-230.
11. Thorbecke GJ, Shah R, Leu CH, Kuruvilla AP, Hardison AM, Palladino MA: Involvement of endogenous tumour necrosis factor« and transforming growth factor i during induction of collagen type II arthritis in mice, Proc Natl Acad Sei USA 1992;89:7375-7379.
12. Piguet PF, Grau GE, Vesin C, Loetscher II, Gcntz R, Lesslauer W: Evolution of collagen arthritis in mice is arrested by treatment with antitumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor, Immunology 1992;77:510-514.
13. Williams RO, Feldmann M, Maini RN: Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis, Proc Natl Acad Sei USA 1992;89:9784-9788.
14. Keffer J, Probcrt L, Cazlaris H, Gcorgopoulos S, Kaslaris E, Kioussis D, Kollias G: Transgenic mice expressing human tumour necrosis factor: A predictive genetic model of arthritis, EMBO J 1991; 10:4025 -4031.
15. Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Katsikis P, Brennan FM, Walker J, Bijl H, Ghrayeb J, Woody J: Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to TNFw, Arthritis Rheum 1993:36: 1681-1690.
16. Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolcn JS, Lceb B, Brecdvcld FC, Macfarlane JD, Bijl H, Woody JN: Randomised double blind comparison of a chimacric monoclonal antibody to tumour necrosis factor (cA2) versus placebo in rheumatoid arthritis, Lancet 1994:344:1105-1110.
17. Rankin ECC, Choy EHS, Kassimos D, Kingsley GH, Sopwith SM, Isenberg DA, Panayi GS: The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CD571) in rheumatoid arthritis, Br J Rheumatol 1995:34:334-342.
18. Feldmann M, Brennan FM, Maini RN: Role of cytokines in autoimmune disease; in Aggarwal RK, et al (eds): Human Cytokines: Their Role in Disease and Therapy, Oxford, Blackwell Science 1995, pp 185-194.
19. Feldmann M, Brennan FM, Maini RN: Rheumatoid arthritis, Cell 1996;85:307-310.
20. Tak TP, Taylor PC, Breedveld FC, Smeets TJM, Daha MR, Klicn PM, Meinders AF., Maini RN: Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis, Arthritis Rheum 1996;39:1077-1081.
21. Palcolog EM, Hunt M, Elliott MJ, Woody JN, Feldmann M, Maini RN: Monoclonal anti-tumour necrosis factor a antibody deactivates vascular endothelium in rheumatoid arthritis, Arthritis Rheum 1996;39:1082-1091.
22. Brcsnihan B, Mulherin D, FitzGerald O: Synovial pathology and articular erosion in rheumatoid arthritis, Rheumatol Eur 1995;24(S): 158-160.
23. Brennan FM, Brown KA, Green PA, Jasper J-M, Maini RN, Feldmann M: Reduction of serum matrix mctalloprotcinasc I and matrix met-alloproteinase 3 in RA patients following anti-TNFa (cA2) therapy, Submitted.
24. Williams RO, Mason LJ, Feldmann M, Maini RN: Synergy between anti-CD4 and anti-TNF in the amelioration of established collagen-induced arthritis, Proc Natl Acad Sci USA 1994; 91:2762-2766.